Innovations and Challenges in Renal Cell Carcinoma: Summary Statement from the Second Cambridge Conference
暂无分享,去创建一个
Mark A Rosen | Michael B Atkins | Keith T Flaherty | W Marston Linehan | T. Libermann | R. Figlin | K. Flaherty | W. Linehan | W. Kaelin | M. Atkins | C. Wood | J. Sosman | M. Rosen | A. Pantuck | B. Rini | V. Sukhatme | M. Ernstoff | D. George | J. Vieweg | M. Rosen | D. McDermott | Jeffrey A Sosman | Daniel J George | David F McDermott | Allan J Pantuck | Robert A Figlin | Towia A Libermann | Brian I Rini | William G Kaelin | A. Ochoa | Augusto C Ochoa | E. Kwon | Christopher G Wood | Marc S Ernstoff | Vikas P Sukhatme | Eugene D Kwon | Johannes W Vieweg | Laura King | L. King
[1] R. Figlin,et al. A phase 3, randomized, 3-arm study of temsirolimus (TEMSR) or interferon-alpha (IFN) or the combination of TEMSR + IFN in the treatment of first-line, poor-risk patients with advanced renal cell carcinoma (adv RCC). , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] R. Motzer,et al. Phase 2 trials of SU11248 show antitumor activity in second-line therapy for patients with metastatic renal cell carcinoma (RCC) , 2005 .
[3] W Marston Linehan,et al. Focus on kidney cancer. , 2004, Cancer cell.
[4] R. Bukowski,et al. Randomized phase III trial of the Raf kinase and VEGFR inhibitor sorafenib (BAY 43–9006) in patients with advanced renal cell carcinoma (RCC) , 2005 .
[5] Suzanne F. Jones,et al. A phase I study with tumor molecular pharmacodynamic (MPD) evaluation of dose and schedule of the oral mTOR-inhibitor Everolimus (RAD001) in patients (pts) with advanced solid tumors , 2005 .
[6] R. Figlin,et al. Phase III randomized trial of sunitinib malate (SU11248) versus interferon-alfa (IFN-{alpha}) as first-line systemic therapy for patients with metastatic renal cell carcinoma (mRCC) , 2006 .
[7] S. Rosenberg,et al. Cancer immunotherapy: moving beyond current vaccines , 2004, Nature Medicine.
[8] R. Figlin,et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] S. Liou,et al. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.